EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Low-dose oral methotrexate versus oral prednisolone for eruptive lichen planus: A randomized comparative pilot study

Kalani Samarasinghe, Chalukya Gunasekera

Sri Lanka Journal of Dermatology · 08.06.2026 · 25 (1) · 24-32

DOI: 10.4038/sljd.v25i1.417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sri Lanka Journal of Dermatology, online erschienen am 08.06.2026. Verfasst von Kalani Samarasinghe und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eruptive lichen planus is a rare and severe variant characterised by widespread cutaneous involvement, intense pruritus, and frequent relapses. Systemic corticosteroids are commonly used but are associated with significant adverse effects and relapse. Low-dose methotrexate has emerged as a potential alternative.

Objectives

To compare the efficacy, safety, and relapse rates of oral prednisolone and oral low-dose methotrexate in eruptive lichen planus.

Methods

A randomized single-blind comparative pilot study was conducted among 30 patients attending the dermatology clinic at the National Hospital of Sri Lanka. Participants were allocated using computer-generated randomisation with allocation concealment via sealed envelopes. Patients received either oral prednisolone (0.5 mg/kg/day) or methotrexate (10–15 mg/week) for 16 weeks. Outcomes were assessed using the pruritus Numerical Rating Scale (0–10) and percentage body surface area (BSA) involvement. Intention-to-treat analysis was performed.

Results

Early partial response at 4 weeks was higher in the prednisolone group (66.7% vs 26.7%; p=0.028). At 16 weeks, complete response rates were comparable (86.7% vs 66.6%; p>0.05). Relapse at 6 months was higher in the steroid group (26.7% vs 6.7%). Adverse events were comparable.

Conclusions

Prednisolone provides faster disease control, while methotrexate may reduce relapse. Methotrexate is a safe and effective alternative.

Zitieren

APA

Samarasinghe, K., & Gunasekera, C. (2026). Low-dose oral methotrexate versus oral prednisolone for eruptive lichen planus: A randomized comparative pilot study. Sri Lanka Journal of Dermatology, 25(1), 24-32. https://doi.org/10.4038/sljd.v25i1.417

Vancouver

Samarasinghe K, Gunasekera C. Low-dose oral methotrexate versus oral prednisolone for eruptive lichen planus: A randomized comparative pilot study. Sri Lanka Journal of Dermatology. 2026;25(1):24-32. doi:10.4038/sljd.v25i1.417

BibTeX
@article{Samarasinghe2026,
  author = {Samarasinghe, Kalani and Gunasekera, Chalukya},
  title = {Low-dose oral methotrexate versus oral prednisolone for eruptive lichen planus: A randomized comparative pilot study},
  journal = {Sri Lanka Journal of Dermatology},
  year = {2026},
  volume = {25},
  number = {1},
  pages = {24--32},
  doi = {10.4038/sljd.v25i1.417}
}
Kostenlos starten →